Prof Shahneen Sandhu
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
540 Scholarly works
15 Projects
HIGHLIGHTS
2026
Journal article
Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer
DOI: 10.1186/s13059-026-04074-22026
Journal article
Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma – The early Australian experience
DOI: 10.1016/j.ejca.2026.1168652026
Journal article
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.
DOI: 10.1158/1078-0432.CCR-25-39512020
Research grants (ARC, NHMRC, MRFF)
Circulating Tumour DNA guidEd Therapy for Stage IIB/C BRAF Mutant Positive mElanoma After surgiCal resecTION (DETECTION)
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2017
Conference Proceedings
Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA
DOI: 10.1093/annonc/mdx370.0022017
Research grants (other domestic)
Novel Approaches for Overcoming Resistance to Therapies for Advanced Melanoma
RECENT SCHOLARLY WORKS
2026
Journal article
Germline CDK12 variants in aggressive prostate cancer.
DOI: 10.1158/2159-8290.CD-26-00842026
Journal article
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
DOI: 10.1158/1078-0432.CCR-25-40012026
Journal article
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma
DOI: 10.1016/j.annonc.2026.04.0102026
Journal article
Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy.
DOI: 10.2967/jnumed.126.2725312026
Journal article
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.
DOI: 10.1038/s41467-026-74334-z2026
Journal article
Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.
DOI: 10.1038/s41467-026-74076-y2026
Journal article
NeoIRENIE: A phase 2 randomized trial of intensified neoadjuvant therapy for melanoma patients with multi-omic biomarker or clinically predicted poor response to standard immune checkpoint inhibitor (ICI) therapy.
DOI: 10.1200/jco.2026.44.16_suppl.tps9610
RECENT PROJECTS
2026
Research grants (other domestic)
Understanding Novel Regulators of Cancer Immunotherapy